ストックスクリーナーアプリを入手
143.77
2.28%
-3.35
アフターアワーズ：
143.85
0.08
+0.06%
前日終値:
$147.12
開ける：
$145.92
24時間の取引高:
7.99M
Relative Volume:
1.10
時価総額：
$178.37B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
21.20
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-4.86%
1か月 パフォーマンス:
+4.35%
6か月 パフォーマンス:
+25.29%
1年 パフォーマンス:
+30.16%
1日の値動き範囲:
$143.09
$146.36
1週間の範囲:
$143.09
$153.25
52週間の値動き範囲:
$93.37
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
143.77 | 182.53B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
1,022.02 | 970.55B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.47 | 590.83B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.69 | 401.23B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
203.98 | 319.13B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.51 | 318.38B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace
Gilead Sciences (GILD) HIV Pill Shows Promising Results in Phase 3 Trials - GuruFocus
Gilead reports positive phase 3 data for HIV treatment combo - Investing.com
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials - Intellectia AI
Gilead (GILD) Introduces Promising HIV Treatment in Phase 3 Tria - GuruFocus
Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters
Gilead's New HIV Treatment Shows Promise in Phase 3 Trials - Intellectia AI
Gilead HIV drug combination maintains viral suppression in phase 3 trials - StreetInsider
Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma
Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030 - GlobeNewswire Inc.
Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating - marketscreener.com
UBS reiterates Buy on Gilead stock after Aclx acquisition - Investing.com
UBS reiterates Buy on Gilead stock after Aclx acquisition By Investing.com - Investing.com UK
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… - marketscreener.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead to Acquire Arcellx for Up to $7.8 Billion, Doubling Down on Next-Generation CAR-T Therapy - NAI500
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Arcellx Stock Explodes 77% After Gilead’s $7.8 Billion Takeover Announcement. Here’s What Investors Should Know - TIKR.com
Gilead Sciences acquires biotech company Arcellx for $7.8 billion - AKM.RU
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - TradingView
Gilead’s Arcellx Deal Deepens Oncology Focus And Raises Valuation Questions - simplywall.st
Gilead to acquire Rockville-area cancer drug developer Arcellx in $8B deal - Technical.ly
Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next - TechStock²
Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says - marketscreener.com
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - bioworld.com
Truist reiterates Gilead Sciences stock rating on Arcellx deal - Investing.com UK
GILD touches the ceiling: Gilead Sciences pulls back after tagging upper channel resistance - FXStreet
Gilead's $7.8 Billion Bet on Arcellx: A New Era for Multiple Myeloma Therapy Begins - Investing News Network
Gilead adds to cell therapy portfolio with $8bn acquisition of Arcellx - European Pharmaceutical Review
Gilead Sciences, Inc. $GILD Shares Bought by Nkcfo LLC - MarketBeat
Pharma Pulse: Eli Lilly’s Multi-Dose Breakthrough and Gilead’s $7.8 Billion Oncology Bet - Pharmaceutical Commerce
Gilead acquires US biotech company for nearly USD 8bn - medwatch.com
AXQ Capital LP Buys Shares of 13,757 Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Price Target Increased by 11.73% to 159.01 - Nasdaq
UBS downgrades Arcellx stock rating to neutral on Gilead acquisition - Investing.com
Gilead Strikes $7.8 Billion Deal for Control of Cancer Biotech Arcellx - The Daily Upside
Gilead to buy Arcellx in nearly $8B deal - statnews.com
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition - BioSpace
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
Gilead brings Arcellx fully under the fold for $7.8B - BioWorld MedTech
Gilead’s Bictegravir/Lenacapavir Noninferiority Data Will Support Switching From Biktarvy - Citeline News & Insights
Why Gilead plans to buy a Bay Area company for $7.8 billionSan Francisco Business Times - The Business Journals
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - AOL.com
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J - Investor's Business Daily
Gilead Sciences to Present at Upcoming Investor Conferences - The Joplin Globe
This Biotech Stock Is Having Its Best Day Ever. Gilead Sciences Is Buying It. - Barron's
Gilead Raises $7.8 Billion To Acquire Arcellx And Expand Cancer Pipeline - Ventureburn
Evercore ISI cuts Arcellx stock rating to In Line on Gilead acquisition - Investing.com
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Sale |
154.44 |
28,000 |
4,324,228 |
120,288 |
| Dickinson Andrew D | Chief Financial Officer |
Feb 17 '26 |
Sale |
154.43 |
3,000 |
463,290 |
167,779 |
1.42%
0.04%
大文字化:
|
ボリューム (24 時間):